T-cell receptor beta variable 14 (TRBV14) (TCR Vβ14)

T-cell receptor beta variable 14 (TRBV14), commonly known as TCR Vβ14, is a specific variable region of the T-cell receptor beta chain that plays a critical role in antigen recognition and immune response (UniProt, 2024). In several autoimmune conditions, particularly rheumatoid arthritis (RA) and psoriasis, T-cell populations expressing the Vβ14 chain are often found to be oligoclonally expanded and autoreactive, contributing to chronic inflammation and tissue damage in the synovium and skin (PubMed, 1998; NIH, 2023). These cells can also be specifically activated by superantigens such as the Mycoplasma arthritidis mitogen (MAM), which bypasses conventional antigen processing to trigger massive T-cell activation (PubMed, 2001). Therapeutic strategies targeting TCR Vβ14 include the use of monoclonal antibodies for selective cell depletion and T-cell vaccination using Vβ14-derived peptides to induce regulatory immune responses (PubMed, 2007; NIH, 2023). While these approaches offer the potential for high-precision immunotherapy by sparing the majority of the T-cell repertoire, challenges include ensuring the specificity of the target to pathogenic clones and avoiding broader immunosuppression (Frontiers in Immunology, 2022).

Other names

TRBV14TCRBV14T-cell receptor beta chain variable 14TCR V-beta 14TCRBV14S1

Selective depletion of Vβ14-expressing T cells via monoclonal antibodies or induction of regulatory T-cell responses through T-cell vaccination with Vβ14-derived peptides.